文献速递肾移植肾小球疾病

MGRS相关病变患者的肾移植结局:病例系列

Kidney Transplantation in Patients With Monoclonal Gammopathy of Renal Significance (MGRS)-Associated Lesions: A Case Series.
PubMed 文献 · Am J Kidney Dis · 2021-06-24

该病例系列纳入28例因MGRS相关病变(LCDD、C3G-MG、LCPT)接受肾移植的患者,部分移植前接受克隆导向治疗。移植前治疗者组织学复发、移植物失败和死亡比例较低;移植前达完全血液学缓解者无死亡且移植物失败少。结论认为MGRS相关病变肾移植后复发常见,完全血液学缓解可能降低风险。

要点

  • MGRS相关病变肾移植后组织学复发常见
  • 移植前克隆导向治疗与较低复发和移植物失败相关
  • 移植前完全血液学缓解者预后较好

核心结论

  • MGRS相关病变肾移植后复发非常常见。
  • 实现完全血液学缓解可能降低复发、移植物丢失和死亡风险。
  • 需更多研究确定血液学缓解对各MGRS病变结局的影响。

研究设计与样本

  • 病例系列,纳入1987至2016年接受肾移植的28例MGRS相关病变患者。
  • 部分患者移植前接受克隆导向治疗。
  • 病变包括轻链沉积病(LCDD)、伴单克隆丙种球蛋白血症的C3肾小球病(C3G-MG)和轻链近端肾小管病(LCPT)。

主要发现

  • LCDD治疗组19例中10例移植前治疗,3例(30%)组织学复发,2例(20%)移植物失败,2例(20%)死亡,中位随访70(范围3-162)个月。
  • LCDD未治疗组9例中8例(89%)组织学复发,6例(67%)移植物失败,4例(44%)死亡,中位随访60(范围35-117)个月。
  • 移植前完全缓解的5例中无死亡,仅1例移植后162个月移植物失败。
  • C3G-MG 5例中3例移植前未治疗,治疗2例均组织学复发,1例移植物失败并死亡;未治疗3例均组织学复发,2例移植物丢失,1例死亡。
  • LCPT 4例中未治疗3例均组织学复发,2例死亡(1例肾功能正常);治疗1例无组织学复发、无移植物丢失且存活。

临床怎么用

  • 肾移植前应考虑克隆导向治疗以争取完全血液学缓解。
  • 移植后需密切监测MGRS相关病变的组织学复发。

局限性

  • 样本量小。
  • 临床管理非标准化。
  • 回顾性设计。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

RATIONALE & OBJECTIVE: Data on kidney transplantation outcomes among patients with monoclonal gammopathy of renal significance (MGRS) are lacking. STUDY DESIGN: Case series of patients with MGRS, some of whom received clone-directed therapies before kidney transplantation. SETTING & PARTICIPANTS: 28 patients who underwent kidney transplantation from 1987 through 2016 after diagnosis with MGRS-associated lesions including light-chain deposition disease (LCDD), C3 glomerulopathy with monoclonal gammopathy (C3G-MG), and light-chain proximal tubulopathy (LCPT). FINDINGS: Of the 19 patients with LCDD, 10 were treated before kidney transplantation and 9 were treatment-naive. Among the treated patients with LCDD, 3 (30%) experienced histologic recurrence, 2 (20%) grafts failed, and 2 (20%) died during a median follow-up of 70 (range, 3-162) months after transplant. In the treatment-naive LCDD group, 8 (89%) had histologic recurrence, 6 (67%) grafts failed, and 4 (44%) patients died during a median follow-up of 60 (range, 35-117) months. Of the 5 patients who had a complete response before transplant, none died, and only 1 experienced graft failure, 162 months after transplant. Of 5 patients with C3G-MG, 3 were treatment-naive before transplant. Both patients who were treated before transplant had histologic recurrence, and 1 experienced graft failure and died. Among the 3 patients with treatment-naive C3G-MG, histologic recurrence occurred in all, and graft loss and death were observed in 2 and 1, respectively. In the LCPT group (n=4), histologic recurrence was observed in all 3 patients who did not receive clone-directed therapies before transplant, and 2 of these patients died, 1 with a functioning kidney. The 1 patient with LCPT who received therapy before transplant did not have histologic recurrence or graft loss and survived. LIMITATIONS: Small sample size, nonstandardized clinical management, retrospective design. CONCLUSIONS: Recurrence is very common in all MGRS-associated lesions after kidney transplant. Achieving a complete hematologic response may reduce the risks of recurrence, graft loss, and death. More studies are needed to determine the effects of hematologic response on outcomes for each MGRS-associated lesion.

来源:Am J Kidney Dis,查看原文。版权归原作者所有。

引用

  1. Heybeli C, Alexander MP, Bentall AJ, et al. Kidney Transplantation in Patients With Monoclonal Gammopathy of Renal Significance (MGRS)-Associated Lesions: A Case Series. Am J Kidney Dis. 2021. PMID: 34175375. doi:10.1053/j.ajkd.2021.04.015

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。